Arturo Meade, MD
Pulmonary Disease · Fort Smith, ARNPI 1639166556
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $49,975 of the $67,110 with a category attached, or 74.5%. GSK accounts for 77.1% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2021 at $25,639 and has fallen 61.7% since, to $9,809 in 2025. Among pulmonary disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 521 payments — averaging $128.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$52K
- Intuitive Surgical$8K
- AstraZeneca$2K
- Pulmonx Corporation$818
- Boehringer Ingelheim$725
- Regeneron Healthcare Solutions, Inc.$464
- plus $3K from 39 others
What the payments were for
- Speaking & faculty fees$49,97574%
- Travel & lodging$1,5782%
- Food & beverage$8,39713%
- Education$7,16011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$33,198
- Da Vinci Surgical System$7,836
- Pulmonx Endobronchial Valve EBV$657
- FASENRA$598
- BREZTRI$101
- TEZSPIRE$101
How this compares
$67,110 in reported general payments places this provider in the 95th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 65 | $725,661 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 860 | $666,383 |
| Fasenra PenBenralizumab | 66 | $392,179 |
| LumryzSodium Oxybate | 12 | $216,475 |
| Pirfenidone | 74 | $127,055 |
| Breo ElliptaFluticasone/Vilanterol | 224 | $101,722 |
| Dupixent SyringeDupilumab | 12 | $64,949 |
| Spiriva HandihalerTiotropium Bromide | 86 | $54,819 |
| Dupixent PenDupilumab | 14 | $50,721 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 96 | $47,841 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 77 | $40,930 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $34,397 |
| SymbicortBudesonide/Formoterol Fumarate | 116 | $33,883 |
| XolairOmalizumab | 12 | $32,574 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 50 | $26,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $51,757 | $842,7741,259 claims |
| Boehringer IngelheimOfev, Combivent Respimat, Stiolto Respimat, Spiriva Respimat | $725 | $812,221221 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,282 | $81,216182 claims |
| PfizerEliquis | $47 | $16,24718 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $26 | $4,27517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Fort Smith
- Daphne MacbruceFort Smith$10K
- Adebayo FasanyaFort Smith$8K
- Muhammad MirFort Smith$4K
- Sarikun TjandraFort Smith$3K
- Francisco TamayoFort Smith$3K
- Ladly AbrahamConway$371K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.